1.8500 +0.11 (6.32%)
After hours: 6:14PM EDT
Triple Moving Average Crossover
|Bid||1.7700 x 800|
|Ask||1.7800 x 2900|
|Day's Range||1.7000 - 2.0500|
|52 Week Range||0.6260 - 9.5000|
|Beta (5Y Monthly)||5.97|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 14, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Apr 23, 2008|
|1y Target Est||N/A|
AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri" or the "Company"), announced that the Company is continuing to work through the regulatory review process towards finalizing the proposed amalgamation transaction with Jay Pharma, Inc. ("Jay Pharma"), a Canadian company dedicated to developing innovative, evidence-based cannabinoid products and combination therapies to address unmet needs in cancer care (the "Amalgamation"). In connection with the Amalgamation, Ameri will spin-off its existing IT services business to a private entity founded by Ameri management in partnership with Ameri's current Series A Preferred Equity Holders (the "Spin-Off," and collectively, with the Amalgamation, the "Transactions"). The Transactions, which were originally expected to close in the first half of 2020, remain subject to Ameri shareholder approval, approval of the Nasdaq Stock Market, and other customary closing conditions. Ameri filed a Registration Statement on Form S-4 and preliminary Proxy Statement on May 27, 2020, with the Securities and Exchange Commission ("SEC") in connection with Ameri's proposed amalgamation agreement with Jay Pharma (the "transaction"). Once the required regulatory approvals have been obtained, the Company intends to immediately set a date for a special meeting for its shareholders to approve the proposals associated with the Transactions, deliver the final Proxy Statement to its shareholders, and then proceed to expeditiously close the Transactions.
AMERI Holdings, Inc. (NASDAQ: AMRH) (the "Company"), today announced that it has entered into a securities purchase agreement with institutional investors to purchase approximately $1.725 million of its common shares in a registered direct offering priced at-the-market under Nasdaq rules.
Shares of AMERI Holdings Inc. were the biggest gainers and the second-most actively traded on major U.S. exchanges, after the company said that Jay Pharma Inc., the company it is merging into, has received a review board's approval to launch a phase I/II clinical trial of its cannabidiol (CBD) formulation of a treatment for a form of brain cancer (GBM). The company said the final approval of the study from the Israel Ministry of Health is expected this summer. The stock more than tripled (up 222%) in morning trading toward an 8-month high. Volume was 29.4 million shares, compared with the full-day average of about 165,000 shares. AMERI said the phase I/II trial is expected to enroll 40 patients, with half the patients treated with Jay Pharma's orally administered synthetic CBD derived from citrus, and the other half treated with CBD in combination with clomiphene, an estrogen binding site inhibitor. "GBM highly expresses the CB2 cannabinoid receptor, and our hypothesis is that CBD 'opens up' cell pathways and makes them more susceptible to chemotherapy," said Jay Pharma Chief Executive Dave Johnson. AMERI's stock has run up 91% year to date, while the S&P 500 has slipped 5.1%.
AMERI Holdings, Inc. (NASDAQ: AMRH) (the "Company"), today announced that its proposed amalgamation partner Jay Pharma Inc. ("Jay Pharma") received institutional review board ("IRB") approval by Rabin Medical Center in Petah Tikva, Israel for a Phase I/II clinical trial investigating Jay Pharma's proprietary cannabidiol ("CBD") formulation for the treatment of glioblastoma multiforme ("GBM"), a rare and aggressive form of brain cancer. This open-label, two-arm, randomized, prospective study is scheduled to commence following final approval from the Israel Ministry of Health, which is expected this summer.
AMERI Holdings, Inc. (NASDAQ: AMRH) (the "Company"), brings to the attention of its shareholders a Letter to Stakeholders and Investor Presentation published by Jay Pharma Inc. ("Jay Pharma") that provides an overview of the Company's commitment to developing innovative, evidence-based cannabinoid medicines and combination therapies to meet unique and underserved needs in cancer care. The letter, authored by Dave Johnson, chairman and CEO-elect of Jay Pharma, and investor presentation detail Jay Pharma's business strategy, IP, and proposed clinical path both for palliative care and combination therapy products.
AMERI Holdings, Inc. (NASDAQ: AMRH) (the "Company"), brings to the attention of its shareholders a press release issued by Jay Pharma Inc. ("Jay Pharma") today to announce the appointment of George A. Kegler, Jr. to Jay Pharma's Board of Directors and as Audit Committee Chair, to be effective upon the closing of Jay Pharma's anticipated merger transaction with Ameri Holdings.
AMERI Holdings, Inc. (NASDAQ: AMRH) (the "Company"), brings to the attention of its shareholders a press release issued by Jay Pharma Inc. ("Jay Pharma") today to announce the appointment of Sara Dakar as Vice President, Product Development. In her new role, Ms. Dakar will oversee the development and formulation of novel products, including the development of science-backed skincare products utilizing cannabidiol ("CBD") and other evidence-based ingredients.
AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri" or the "Company"), announced today that former CIA Director, the Honorable R. James (Jim) Woolsey, has joined the Company as a strategy consultant. Woolsey will provide Ameri leadership with counsel in the areas of business development and government affairs in the cannabis industry ahead of the closing of its merger with Jay Pharma, a Canadian company dedicated to developing innovative, evidence-based cannabinoid products and combination therapies to address unmet needs in cancer care. Woolsey is a longtime advocate for the commercialization of hemp for industrial use. The Company expects Woolsey to join the board of directors of Jay Pharma upon the close of the merger.
NEW YORK, NY / ACCESSWIRE / January 21, 2020 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased AMERI Holdings, Inc. ("Ameri" or the ...
NEW YORK, NY / ACCESSWIRE / January 21, 2020 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased AMERI Holdings, Inc. ("Ameri") (NASDAQ:AMRH) ...
Jay Pharma, an evidence-based pharmaceutical cannabinoid and wellness company focused on cancer, announced last week a reverse merger with Ameri Holdings Inc (NASDAQ: AMRH). The merger will allow Jay Pharma to expand its body of research and execute on its plans to bring oncology clinicians and researchers together with academic and industry partners to enhance clinically proven products to patients.
Jay Pharma is an evidence-based cannabinoid & wellness company focused on cancer. The company holds an exclusive license with Tikun Olam for cannabinoid intellectual property, including data and genetics for cancer patient care. Jay Pharma’s world class management & oncology teams are developing safe, clinically validated cannabinoid products.
AMERI Holdings, Inc. (AMRH) (“Ameri”) today announced it entered into an amalgamation agreement (the “Amalgamation Agreement”) with Jay Pharma Inc. (“Jay Pharma”), a Canadian company dedicated to developing innovative, evidence-based cannabinoid products and combination therapies to address unmet needs in cancer care, pursuant to which the shareholders of Jay Pharma will become the majority holders of Ameri’s outstanding stock by way of an amalgamation (the “Amalgamation”). In connection with the Amalgamation, Ameri will spin-off its existing IT services business to a private entity founded by Ameri management in partnership with Ameri’s current Series A Preferred Equity Holders (the “Spin-Off,” and collectively, with the Amalgamation, the “Transactions”).
AMERI Holdings, Inc. (AMRH) (the “Company”), a specialized SAP® cloud, digital and enterprise solutions company, announced today that it had received written notice from the Nasdaq Stock Market (“Nasdaq”) Listing Qualifications Staff on December 10, 2019, indicating that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq considers the matter closed. Ameri100 is a fast-growing specialized SAP® cloud, digital and enterprise solutions company which provides SAP® services to customers worldwide.
This is a strategic global win for the Company and will be executed by the global SAP Solutions team based out of the Company’s Bangalore Innovation Center. The project will be utilizing Ameri100’s best-in-class SAP HANA conversion factory model to execute the conversion (migration) from SAP ECC to S/4HANA 1909 addressing necessary code remediation, configuration changes, integration points, customizations, and implementation aspects of the platform, in conjunction with business process re-engineering.
Ameri100 was awarded the approximate $1.0 million contract by the customer based on the Company’s proven track record for S/4HANA implementations and expertise in digital transformation. “The implementation of SAP S/4HANA will deliver to the customer an agile, flexible and best in class ERP environment that modernizes its business processes and advances its overall digital transformation,” stated Ameri100 Chief Executive Officer Brent Kelton.
Ameri100 will support and enhance the integration of the customer’s SuccessFactors Human Experience Management (HXM) Business Suite implementation. SuccessFactors is integral to the customer’s ability to attract and retain personnel tasked with developing solutions in the retail and manufacturing industries. Ameri100 will also utilize SAP’s Cloud Platform Integration (CPI) middleware to create and maintain interfaces with third-party vendors, such as automated payroll services and benefits providers.
The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market. The new CUSIP number for the common stock following the reverse split will be 02362F 302.
This customer, with gross sales in excess of $1.3B and over 2300 employees, has partnered with Ameri100 on their digital transformation journey and implemented the entire SuccessFactors Human Experience Management (HXM) Business Suite. With application management support, the customer can focus its resources on business transformation initiatives to sharpen its competitive advantage and drive growth while Ameri100 manages the day-to-day operations of the SuccessFactors deployment.
AMERI Holdings, Inc. (AMRH) (“Ameri100”), a specialized SAP® cloud, digital and enterprise solutions company, announced that its 2019 Annual Meeting of Stockholders ("Annual Meeting"), scheduled for Tuesday, October 29, 2019, was convened and adjourned, without any business being conducted. The Annual Meeting has been adjourned to 10:00 AM local time on Friday, November 8, 2019 at the offices of Sheppard, Mullin, Richter & Hampton LLP, 30 Rockefeller Plaza, New York, NY 10112, to allow additional time for stockholders to vote on the proposals set forth in Ameri Holdings’ definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on September 27, 2019. Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action.
AMERI Holdings, Inc. (AMRH) (“Ameri100”), a specialized SAP® cloud, digital and enterprise solutions company, announced it is launching a series of joint webinars co-hosted with Google Cloud for current and prospective Ameri100 customers. The webinars will be co-led by Ameri100 and Google Cloud SAP experts to educate customers and prospective customers about the significant benefits and differentiators of moving any size and type of SAP workload to Google Cloud Platform, especially as it relates to S/4HANA and C/4HANA applications. Google Cloud has invested significantly in tailoring its cloud offerings specifically for SAP applications and is rapidly gaining market share in this exponentially growing space.
AMERI Holdings, Inc. (AMRH) (“Ameri100”), a specialized SAP® cloud, digital and enterprise solutions company, announced that it has been selected as the preferred vendor by a new customer, a leading industrial goods manufacturer for commercial and residential applications in the U.S. and Latin America, to perform a business blueprint that will provide a roadmap to transform their current legacy environment to an SAP S/4HANA digital core that will support the company’s rapid growth. The assessment will include a path to transform the current business to an intelligent enterprise by connecting key departments from finance, operations and warehouse management to future business processes. “We continue to advise and provide business value to our customers by helping them connect their business processes and customer and human experiences,” said Brent Kelton, chief executive officer of Ameri100.
AMERI Holdings, Inc. (AMRH) (“Ameri100”), a specialized SAP® cloud, digital and enterprise solutions company, announced that it has been awarded a support contract for post-‘go live’ hypercare from a leading golf lifestyle apparel brand following its recent implementation of SAP S/4HANA 1809 Fashion (the “initial implementation”). Concurrently, the customer has also selected Ameri100 to implement enhanced functionality and additional features into the initial implementation. The initial implementation , part of a digital transformation award secured by Ameri100 in September 2018, is the first step in transforming the customer into an intelligent enterprise.
AMERI Holdings, Inc. (AMRH) (“Ameri100”), a specialized SAP® cloud, digital and enterprise solutions company, announced that it has successfully completed the first SAP S/4HANA 1809 Fashion greenfield implementation in the U.S. The implementation, part of a digital transformation award secured in September 2018 from a golf lifestyle apparel company with annual sales of $1.2 billion, is the first step in transforming the customer into an intelligent enterprise by building a digital platform capable of automating the company's business processes and allows them to interact with their customers and suppliers. In conjunction with the implementation of S/4HANA 1809 Fashion, Ameri100 is also helping the customer implement C/4HANA Commerce (Hybris) by the first quarter of 2020 that will redefine the customer end-to-end experience.
AMERI Holdings, Inc. (AMRH) (“Ameri100”), a specialized SAP® cloud, digital and enterprise solutions company, today announced that it had exchanged all remaining outstanding warrants that were issued as part of a financing in 2018 (the “2018 Warrants”) for shares of Ameri100’s common stock. The company negotiated exchange agreements with the holders of the 15,744,827 outstanding 2018 Warrants, whereby all of such 2018 Warrants were exchanged for 10,234,136 new shares of Ameri100 common stock. Ameri100 is a specialized SAP® cloud, digital and enterprise solutions company which provides SAP® services to customers worldwide.